Literature DB >> 34428095

Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer.

Harshabad Singh1,2,3, Kimberly Perez1,2,3, Brian M Wolpin1,2,3, Andrew J Aguirre1,2,3.   

Abstract

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34428095      PMCID: PMC8500570          DOI: 10.1200/JCO.21.01510

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   50.717


  45 in total

1.  Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative.

Authors:  Michael J Pishvaian; Robert J Bender; David Halverson; Lola Rahib; Andrew E Hendifar; Sameh Mikhail; Vincent Chung; Vincent J Picozzi; Davendra Sohal; Edik M Blais; Kimberly Mason; Emily E Lyons; Lynn M Matrisian; Jonathan R Brody; Subha Madhavan; Emanuel F Petricoin
Journal:  Clin Cancer Res       Date:  2018-06-28       Impact factor: 12.531

2.  Genomic analyses identify molecular subtypes of pancreatic cancer.

Authors:  Peter Bailey; David K Chang; Katia Nones; Amber L Johns; Ann-Marie Patch; Marie-Claude Gingras; David K Miller; Angelika N Christ; Tim J C Bruxner; Michael C Quinn; Craig Nourse; L Charles Murtaugh; Ivon Harliwong; Senel Idrisoglu; Suzanne Manning; Ehsan Nourbakhsh; Shivangi Wani; Lynn Fink; Oliver Holmes; Venessa Chin; Matthew J Anderson; Stephen Kazakoff; Conrad Leonard; Felicity Newell; Nick Waddell; Scott Wood; Qinying Xu; Peter J Wilson; Nicole Cloonan; Karin S Kassahn; Darrin Taylor; Kelly Quek; Alan Robertson; Lorena Pantano; Laura Mincarelli; Luis N Sanchez; Lisa Evers; Jianmin Wu; Mark Pinese; Mark J Cowley; Marc D Jones; Emily K Colvin; Adnan M Nagrial; Emily S Humphrey; Lorraine A Chantrill; Amanda Mawson; Jeremy Humphris; Angela Chou; Marina Pajic; Christopher J Scarlett; Andreia V Pinho; Marc Giry-Laterriere; Ilse Rooman; Jaswinder S Samra; James G Kench; Jessica A Lovell; Neil D Merrett; Christopher W Toon; Krishna Epari; Nam Q Nguyen; Andrew Barbour; Nikolajs Zeps; Kim Moran-Jones; Nigel B Jamieson; Janet S Graham; Fraser Duthie; Karin Oien; Jane Hair; Robert Grützmann; Anirban Maitra; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Richard A Morgan; Rita T Lawlor; Vincenzo Corbo; Claudio Bassi; Borislav Rusev; Paola Capelli; Roberto Salvia; Giampaolo Tortora; Debabrata Mukhopadhyay; Gloria M Petersen; Donna M Munzy; William E Fisher; Saadia A Karim; James R Eshleman; Ralph H Hruban; Christian Pilarsky; Jennifer P Morton; Owen J Sansom; Aldo Scarpa; Elizabeth A Musgrove; Ulla-Maja Hagbo Bailey; Oliver Hofmann; Robert L Sutherland; David A Wheeler; Anthony J Gill; Richard A Gibbs; John V Pearson; Nicola Waddell; Andrew V Biankin; Sean M Grimmond
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 4.  Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.

Authors:  Dongsung Kim; Jenny Yaohua Xue; Piro Lito
Journal:  Cell       Date:  2020-10-15       Impact factor: 41.582

5.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

Authors:  Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael
Journal:  Lancet       Date:  2010-07-06       Impact factor: 79.321

6.  Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

Authors:  Andrew J Aguirre; Jonathan A Nowak; Nicholas D Camarda; Richard A Moffitt; Arezou A Ghazani; Mehlika Hazar-Rethinam; Srivatsan Raghavan; Jaegil Kim; Lauren K Brais; Dorisanne Ragon; Marisa W Welch; Emma Reilly; Devin McCabe; Lori Marini; Kristin Anderka; Karla Helvie; Nelly Oliver; Ana Babic; Annacarolina Da Silva; Brandon Nadres; Emily E Van Seventer; Heather A Shahzade; Joseph P St Pierre; Kelly P Burke; Thomas Clancy; James M Cleary; Leona A Doyle; Kunal Jajoo; Nadine J McCleary; Jeffrey A Meyerhardt; Janet E Murphy; Kimmie Ng; Anuj K Patel; Kimberly Perez; Michael H Rosenthal; Douglas A Rubinson; Marvin Ryou; Geoffrey I Shapiro; Ewa Sicinska; Stuart G Silverman; Rebecca J Nagy; Richard B Lanman; Deborah Knoerzer; Dean J Welsch; Matthew B Yurgelun; Charles S Fuchs; Levi A Garraway; Gad Getz; Jason L Hornick; Bruce E Johnson; Matthew H Kulke; Robert J Mayer; Jeffrey W Miller; Paul B Shyn; David A Tuveson; Nikhil Wagle; Jen Jen Yeh; William C Hahn; Ryan B Corcoran; Scott L Carter; Brian M Wolpin
Journal:  Cancer Discov       Date:  2018-06-14       Impact factor: 39.397

7.  Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.

Authors:  Jung Won Chun; Sang Hyub Lee; Joo Seong Kim; Namyoung Park; Gunn Huh; In Rae Cho; Woo Hyun Paik; Ji Kon Ryu; Yong-Tae Kim
Journal:  BMC Cancer       Date:  2021-05-11       Impact factor: 4.430

8.  Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.

Authors:  Laetitia Dahan; Nicolas Williet; Karine Le Malicot; Jean-Marc Phelip; Jérôme Desrame; Olivier Bouché; Caroline Petorin; David Malka; Christine Rebischung; Thomas Aparicio; Cédric Lecaille; Yves Rinaldi; Anthony Turpin; Anne-Laure Bignon; Jean-Baptiste Bachet; Jean-François Seitz; Come Lepage; Eric François
Journal:  J Clin Oncol       Date:  2021-07-21       Impact factor: 44.544

9.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962

10.  Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.

Authors:  Suayib Yalcin; Faysal Dane; Berna Oksuzoglu; Nuriye Yildirim Ozdemir; Abdurrahman Isikdogan; Metin Ozkan; Guzin Gonullu Demirag; Hasan Senol Coskun; Bulent Karabulut; Turkkan Evrensel; Mehmet Ali Ustaoglu; Feyyaz Ozdemir; Hande Turna; Tugba Yavuzsen; Faruk Aykan; Alper Sevinc; Hakan Akbulut; Deniz Yuce; Mutlu Hayran; Saadettin Kilickap
Journal:  BMC Cancer       Date:  2020-03-30       Impact factor: 4.430

View more
  2 in total

1.  It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer.

Authors:  Ingrid Garajová; Andrea Cavazzoni; Michela Verze; Roberta Minari; Giuseppe Pedrazzi; Rita Balsano; Fabio Gelsomino; Raffaele Dalla Valle; Graziana Digiacomo; Elisa Giovannetti; Francesco Leonardi
Journal:  Life (Basel)       Date:  2022-06-26

2.  The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel Approach.

Authors:  Lenka N C Boyd; Mahsoem Ali; Laura Kam; Jisce R Puik; Stephanie M Fraga Rodrigues; Eline S Zwart; Freek Daams; Barbara M Zonderhuis; Laura L Meijer; Tessa Y S Le Large; Elisa Giovannetti; Hanneke W M van Laarhoven; Geert Kazemier
Journal:  Cancers (Basel)       Date:  2022-01-11       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.